RENTA 4 UNIVERSAL, FI

Leaves the portfolio; it was 2.29% of weight.

Leaves the portfolio; it was 1.96% of weight.

Leaves the portfolio; it was 1.25% of weight.

Leaves the portfolio; it was 1.23% of weight.

Leaves the portfolio; it was 0.96% of weight.

Leaves the portfolio; it was 0.83% of weight.

ArcelorMittal S.A., together with its subsidiaries, operates as integrated steel and mining companies in the Americas, Europe, Asia, and Africa. It offers semi-finished flat products, including slabs; finished flat products comprising plates, hot- and cold-rolled coils and sheets, hot-dipped and electro-galvanized coils and sheets, tinplate, and color coated coils and sheets; semi-finished long products, such as blooms and billets; finished long products consisting of bars, wire-rods, structural sections, rails, sheet piles, and wire-products; and seamless and welded pipes and tubes. The company also provides mining products, such as iron ore lumps, fines, concentrate, pellets, and sinter feeds; and coking coal. It sells its products to various customers in the automotive, appliance, engineering, construction, energy, and machinery industries through a centralized marketing organization, and distributors. The company operates iron ore mining activities in Brazil, Bosnia, Liberia, Mexico, South Africa, and Ukraine, as well as in India and in Canada. ArcelorMittal S.A. was founded in 1976 and is headquartered in Luxembourg, Luxembourg.

Leaves the portfolio; it was 0.66% of weight.

Leaves the portfolio; it was 0.42% of weight.

Goes from 6.40% to 0.72%.

Goes from 2.63% to 0.60%.

Goes from 3.43% to 1.83%.

Goes from 1.83% to 0.89%.

Goes from 1.93% to 1.11%.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Goes from 1.02% to 0.32%.

Goes from 1.03% to 0.38%.

Goes from 2.43% to 1.80%.

Goes from 1.49% to 0.95%.

Goes from 1.16% to 0.69%.

Goes from 1.31% to 0.99%.

Goes from 1.54% to 1.24%.

Goes from 0.51% to 0.24%.

Goes from 0.43% to 0.21%.

Goes from 0.81% to 0.60%.